SHANGHAI, Aug. 5, 2024
/PRNewswire/ -- Recently,
CorrectSequence Therapeutics Co., Ltd. (Correctseq)
announced a significant milestone in their base editing therapy
CS-101 for transfusion-dependent β-thalassemia. Utilizing their
pioneering transformer Base Editor (tBE), Correctseq has
successfully cured the first overseas patient with
transfusion-dependent β-thalassemia in a clinical trial in
collaboration with the First Affiliated Hospital of Guangxi Medical
University. The patient has achieved a sustained transfusion-free
status for over two months, with the hemoglobin level stabilized at
above 120 g/L. As a result, the patient has been able to resume a
normal life. This milestone marks China's first documented report of an overseas
patient being clinically cured through gene editing
therapy. OBiO Technology (Shanghai) Corp., Ltd. (OBiO
Technology) extends its heartfelt congratulations and best wishes
to the patient who has been cured, and warmly congratulates the
partner Correctseq on this significant progress.
The Phase I clinical trial for the treatment of β-thalassemia
with CS-101 is proceeding steadily. In tandem, a clinical trial
targeting sickle cell disease (SCD) with CS-101 are in active
preparation. A global recruitment program for SCD patients is
recently launched.
OBiO Technology is a leading CDMO company specializing in cell
and gene therapy in China,
equipped with 15 GMP vector production lines and 20 GMP cell
therapy production lines. As a reliable partner with Correctseq,
OBiO Technology has provided solid support for CS-101, including
process development, analytical development, production and IND
filling services. OBiO Technology celebrates the significant
achievements made in treating patients with CS-101, affirming the
successful collaboration between the two companies. Driven by
innovation and united in purpose, we believe our close partnership
will bring hope and a brighter future to patients worldwide!
About CorrectSequence Therapeutics
CorrectSequence
TherapeuticsTM (CorrectseqTM), is a
clinical-stage biotech company employing its proprietary
transformer Base Editor (tBE) to pioneer next-generation gene
editing therapies. Our leading pipeline candidate, CS-101,
utilizing innovative base editor targeting HBG, curing
β-hemoglobinopathies, has obtained IND approval from the China
NMPA. Clinical data demonstrate its superior performance.
Proof-of-concept (POC) data in mice for in
vivo pipelines using tBE-editing therapies via lipid
nanoparticle (LNP) delivery are available, including targets for
metabolic dysfunction and associated diseases. Ex
vivo multiplex editing of T cells on multiple targets
simultaneously preserved T cell growth and function in
vivo compared to non-edited cells, establishing tBE as the
ideal gene editing tool for the next-generation cell therapy
development. We are developing multiple pipeline programs targeting
genetic diseases, metabolic disorders, and cardiovascular
diseases.
Please refer to our homepage for more information about the tBE
and its therapeutics applications
at www.correctsequence.com
About OBiO Technology
Established in 2013, OBiO Technology is a pioneering
Contract Research Organization (CRO) and Contract Development and
Manufacturing Organization (CDMO) in gene and cell therapy,
offering comprehensive solutions. Our unwavering dedication ensures
high-quality CRO and CDMO services for consumers
worldwide across preclinical, IND, clinical, and commercial stages,
including plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy
(CAR-T, NK, Treg, iPSCs), exosomes, and cutting-edge technologies
like inducible viral vector packaging, ultralow endotoxin
processes, and AAVneO screening for tissue-specific AAV variants.
Guided by our mission "Enable Gene Therapy for Better
Lives", we are dedicated to delivering top-tier services
globally. From bench to clinic, we are committed to advancing your
product and benefiting populations worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/obio-technology-congratulates-on-the-first-clinical-gene-editing-therapy-to-treat-an-overseas-patient-in-china-by-correctsequence-therapeutics-302214995.html
SOURCE OBiO Technology (Shanghai) Corp., Ltd.